Infection, Human Immunodeficiency Virus Clinical Trial
Official title:
A Two-way Drug Interaction Study to Evaluate the Effect of BMS-955176 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176
Verified date | January 2017 |
Source | ViiV Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176
Status | Completed |
Enrollment | 14 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Signed Informed Consent 2. Target population: Healthy males and females. 3. Women of child bearing potential (WOCBP) with negative serum pregnancy test 4. Women must not be breastfeeding 5. Men and WOCBP must agree to follow instructions for contraception Exclusion Criteria: 1. History of any chronic or acute illness, gastrointestinal disease, GI surgery, cardiac disease or clinically significant cardiac arrhythmia 2. History of frequent headaches or acute diarrhoea. 3. Any major surgery within 4 weeks of study drug administration 4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population 5. History of allergy to HIV maturation and integrase inhibitors,or related compounds 6. History of smoking |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare | GlaxoSmithKline |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum observed plasma concentration (Cmax) for DTG | Days 1 to 5 and days 15 to 21 | ||
Primary | Area under the concentration-time curve in 1 dosing interval AUC (tau) for DTG | Days 1 to 5 and days 15 to 21 | ||
Primary | Maximum observed plasma concentration (Cmax) for BMS-955176 | Days 8-21 | ||
Primary | Area under the concentration-time curve in 1 dosing interval AUC (tau) for BMS-955176 | Days 8-21 | ||
Secondary | Adverse events (AEs) | The incidence of observed AEs will be tabulated and reviewed for potential significance and clinical importance. | Days 1-21; for SAEs up to 30 days post discontinuation of dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01425099 -
Drug Interaction Study Between Dolutegravir and Prednisone
|
Phase 1 | |
Completed |
NCT01209117 -
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
|
Phase 1 | |
Completed |
NCT03231943 -
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT01195974 -
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
|
Phase 1 | |
Completed |
NCT02893488 -
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
|
Phase 1 | |
Terminated |
NCT01199731 -
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
|
Phase 2 | |
Completed |
NCT01449929 -
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
|
Phase 3 | |
Active, not recruiting |
NCT02951052 -
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
|
Phase 3 | |
Completed |
NCT01231516 -
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
|
Phase 3 | |
Completed |
NCT02273947 -
Food Effect Study With BMS-955176
|
Phase 1 | |
Completed |
NCT00071760 -
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
|
Phase 2 | |
Completed |
NCT02539576 -
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT01967771 -
Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT00774735 -
GSK1349572 Drug Interaction Study With Protease Inhibitors
|
Phase 1 | |
Completed |
NCT01077635 -
PENTA Fosamprenavir Study
|
N/A | |
Completed |
NCT00386347 -
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00945282 -
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
|
Phase 2 | |
Terminated |
NCT02576119 -
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
|
Phase 1 | |
Completed |
NCT02277600 -
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
|
Phase 1 | |
Completed |
NCT01077557 -
Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
|
N/A |